Introduction
Contrast-induced nephropathy, recently renamed "contrast-associated acute kidney injury (CA-AKI)" or "postcontrast AKI (PC-AKI)" is considered an iatrogenic cause of AKI with adverse short-and long-term outcomes [1] . Over the past years, the evidence for a causal association between contrast and AKI has been challenged. We use the Bradford-Hill criteria to re-evaluate this relationship.
Discussion

Strength of association
The reported incidence of CA-AKI is variable (1-30%), and also a wide range of risk ratios for mortality after CA-AKI (range 0.79-9.52) have been described [1] . This variability suggests that there may be a weaker association between contrast exposure and AKI per se; this, in turn, could be highly influenced by other risk factors for AKI. The heterogeneity among study designs and CA-AKI definitions also contributes to this variability.
Consistency
In the absence of randomized controlled trials, the evidence for CA-AKI must rely on observational data. Recent reports debate the association between contrast exposure and AKI in different settings (Table 1) . A meta-analysis of studies comparing patients with and without intravenous (IV) contrast imaging described no increased incidence of AKI, dialysis, or death with contrast [2] . To reduce selection bias, several subsequent studies have used propensity score matching. Most studies found no difference in the incidence of AKI among matched patients. Subgroup analyses based on baseline kidney function also did not show any differences, except for the study by Davenport that found a higher AKI incidence after contrast in advanced chronic kidney disease (CKD) [3] . McDonald found a greater need for dialysis in ICU patients with pre-CT eGFR ≤ 45 ml/l/BSA (6.7% vs 2.5%; OR 2.72 (1.44-6.46), however, without impact on the AKI creatinine criterion [4] .
Other studies, including some with intra-arterial contrast, demonstrate that AKI incidence is the same in the matched patients, regardless of exposure to contrast. Caspi et al. showed no difference in the AKI incidence between primary PCI (contrast group) and fibrinolysis or no reperfusion (no contrast group) in patients with ST-segment elevation myocardial infarction [12] . Wilhelm-Leen et al. found a lower AKI incidence in patients receiving "any contrast. " However, the diagnosis of both AKI and contrast administration was based on ICD-9 codes, no temporal relation was assessed, and risk factor adjustment was limited [13] . It is interesting that in one study, the Mehran risk score for CA-AKI had the same predictive power in patients with and without contrast [11, 14] .
Some caution in the interpretation of these case-control studies is warranted because even propensity score matching cannot correct for unmeasured or unknown confounders. In addition, most of these studies do not provide data on prophylactic measures (including prehydration) that might be different in cases and controls.
Temporality
There is a consistent temporal relationship described in all studies (observed vasoconstriction of afferent arterioles after exposure to contrast media in animal models and AKI after exposure to contrast in clinical studies); however, the current literature suffers from selection bias and suboptimal trial design. For example, in none of the previous studies investigators attempted to identify subclinical AKI prior to enrollment; therefore, it may have resulted in the inclusion of the patients who had tubular injuries before contrast exposure.
Dose-response relationship
The contrast dose is considered a significant risk factor of CA-AKI both in experimental settings and in humans undergoing cardiac angiography. Contrast dose is included in CA-AKI risk scores [7] but may be confounded by indication. For example, patients with diabetes and chronic kidney disease have a higher risk for CA-AKI but frequently also have multi-vessel disease, which requires a higher dose of contrast during coronary angiography. Furthermore, few studies report the severity of AKI, thus limiting documentation of a dose-response relationship.
Plausibility
The primary proposed mechanisms of CA-AKI are direct cellular toxicity and vasoconstriction. Studies that focus on the use of cytoprotective and vasodilatory medications for CA-AKI prevention have yielded inconsistent results [5, [15] [16] [17] . Such variability in the documentation of benefit of interventions that address the underlying mechanisms may indicate their inefficacies in CA-AKI prevention and also could reflect the limited clinical importance of contrast toxicity. In addition, even if these interventions show benefit, it may not necessarily be related to prevention of contrast toxicity. For example, a recent study suggests that the protective effect of statins in patients with acute coronary syndrome undergoing coronary intervention is only seen in patients with high CRP, a parameter of inflammation that by itself is a risk factor for AKI amenable by statins [18] . Also, the improvement of kidney function with hydration is not specific to CA-AKI [19] .
Coherence
There has been some coherency between the basic research findings with clinical observations. In cell culture models with renal endothelial and epithelial cells, contrast media lead to cell damage [15] [16] [17] . However, in animal models, pre-exposure to other kidney insults (dehydration, nephrotoxins, etc.) is necessary before CA-AKI development. This is coherent with the clinical scenarios where AKI is rarely seen when contrast is the only exposure and patients need multiple insults before CA-AKI develops.
Experimental data
Although several studies demonstrate that intravenous hydration combined with cytoprotective drugs can potentially prevent CA-AKI, this is not a consistent finding. Some of the interventions may directly impact the serum creatinine concentration independent of the GFR (decreased production, dilution, osmolar loadinduced augmented renal clearance). Hence, observed CA-AKI prevention by these interventions could be solely due to biases of the diagnostic test (serum creatinine).
Alternate explanations
Studies that reported a relationship between contrast exposure and AKI rarely consider alternative causes of AKI. Since most patients receiving contrast have other AKI risk factors or kidney insults, and there is no CA-AKI-specific test or biomarker to exclude alternative causes of AKI, attributing the causal relationship that is reported in the CA-AKI literature is challenging.
Specificity
CA-AKI definition has two distinct components: "0.3 mg/ dl or 50% increase in creatinine within 24-72 h after contrast" and "cannot be attributed to other causes"; the latter element is often neglected, or difficult to determine on the basis of study design/data limitations. Besides the traditional risk factors including CKD, diabetes, age, hypertension, congestive heart failure, high osmolality, or high dose contrast, many patients who receive contrast have other AKI risk factors including dehydration, hypovolemia, low cardiac output, inflammation, sepsis, nephrotoxins, atheroembolism, etc. Results of current literature may be biased on the basis of the lack of specificity of defining CA-AKI in administrative and other datasets.
Conclusion
Applying the Bradford-Hill criteria to evaluate the causality relationship between contrast and AKI reveals significant uncertainty that is also reflected in the ongoing debate in contemporary literature. Considering the available data, we must conclude that the risk of contrast nephropathy is probably not zero but much lower than previously estimated and mainly confined to patients with multiple risk factors. Quantifying the magnitude of the CA-AKI risk requires more sophisticated studies and analyses than currently exist. In clinical practice, decisions regarding contrast administration should weigh individual risk factors with the diagnostic yield and therapeutic consequences of the imaging procedure. Future research should test appropriate implementation of individualized preventative measures in high-risk individuals.
